- Canadian research council says CanSino injections have not been approved to be sent from China
- Council says it is still working with Tianjin company and trials will start when the shots are delivered
Clinical trials in Canada of an early Chinese front runner in the race for a coronavirus vaccine are in limbo, with Chinese customs authorities holding up shipment of the injections for weeks.
Health Canada gave approval for clinical trials for Ad5-nCoV, a potential vaccine developed jointly by Tianjin-based CanSino Biologics and Chinese military scientists, on May 16.
The scientist in charge of the trials, Dalhousie University professor Scott Halperin, said in mid-May that he expected the first of the three phases of trials to start later that month. But Halperin said three weeks ago that he had yet to receive the vaccines for the trials.
Health Canada said the vaccines were held up by China’s General Administration of Customs.
On Thursday, the National Research Council of Canada (NRC) confirmed to the South China Morning Post that the customs administration had still not allowed the shipment to proceed.
“The vaccine candidate for phase 1 clinical trials has not yet been approved by Chinese customs for shipment to Canada,” the council said.